Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer
Andrea R. Hagemann, Kimberly K. Leslie(University of New Mexico)
Cited by 12
Related Papers
TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
|International Journal of Oncology|2014|97
EGFR isoforms and gene regulation in human endometrial cancer cells
|Molecular Cancer|2010|56
Knockdown of MTDH Sensitizes Endometrial Cancer Cells to Cell Death Induction by Death Receptor Ligand TRAIL and HDAC Inhibitor LBH589 Co-Treatment
|PLoS ONE|2011|54
Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets
|The Journal of Steroid Biochemistry and Molecular Biology|2023|2